Eli Lilly axes 163 Dermira staffers, shutters Menlo Park site as it closes in around Dupixent rival lebrikizumab

Eli Lilly made it clear when it shelled out $1.1 billion for Dermira that lebrikizumab is really what it wanted to buy. One year in, the pharma giant is completing its cleavage of the rest.

Days after unveiling the sale of Qbexza — Dermira’s only approved product, a piece...

Click to view original post